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Abstract
We introduced recently a model that takes into account mutation and drug resistance of tu-
mor cells in a case of simple immune system and immune-suppression caused by the resistant
cells. The present study is to apply the Nonstandard finite difference method to that model we
recently developed in analyzing the stability of non-tumor states to identify under which con-
ditions tumor can be eliminated in the presence of both immunotherapy and chemotherapy.
Numerical simulations of the model in the presence of both immunotherapy and chemother-
apy are performed with the aid of MATLAB software using ode45 function and under differ-
ent treatment strategies to analyze the behavior of both the tumor and immune system cells.
The findings of this study indicates that tumor cells can be only eliminated under certain
conditions, when a second specific chemotherapy drug that is only toxic to resistant tumor
cells is introduced. Moreover, it gives an insight into how tumor and immune system cells
evolve when the dynamical system conveys both inherent and drug-induced resistance with
immune-suppression, in the presence of both immunotherapy and chemotherapy. Treatment
strategies effective are proposed in this case.
Keywords: Cancer Modeling, Drug resistance, Mutation, Immune system, Immunotherapy,
Immune-Suppression, Chemotherapy, Nonstandard Finite-Difference Method/Scheme.
AMS Subject Classifications: 37C75; 65L12; 92C37; 68U20.
1 Introduction
To improve the therapeutic approach according to the type and proliferation rate of tumor cells during
cancer treatment, many researchers and mathematicians such as Feizabadi & Witten[1, 3, 6], Kirschner
1Corresponding author: altogbe@gmail.com.
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& Panetta[4], Feizabadi[2], and Kirschner & Tsygvintsev[5] introduced mathematical models to analyze
the evolution of cells. Feizabadi in [2] modeled multi-mutation and drug resistance and assessed the re-
sponse of the time varying cell population under various treatment strategies[23]. In [10], we added in
the model of [2] the effect of a basic immune system and the suppression of immunity caused by drug
resistant tumor cells[24]. The model have been analyzed mathematically and simulated numerically in
the presence of only immunotherapy drug to determine its effectiveness.
In this paper which is an extension of our previous work [10], we employ the Non-Standard Finite-
Difference(NSFD) method proposed by Mikens in [25] in our model to analyze the stability of non-tumor
states in order to identify under which conditions tumor can be eliminated in the presence of both im-
munotherapy and chemotherapy. Then, we simulate numerically the model in the presence of both im-
munotherapy and chemotherapy drug under different treatment strategies to determine the behavior of
both tumor and immune system cells[26]. Treatment strategies effective are proposed for this purpose.
Introduced by Mickens around 1980, the nonstandard finite difference (NSFD)schemes is chosen for
this study because it preserves the important properties of differential equations [11, 27]. At the begin-
ning, the general rules for implementing these schemes were vaguely known[12, 28]. However, Mickens
proposed some rules for constructing nonstandard schemes for differential equations[13]. Used by many
mathematicians such as R. Anguelov et al[14]; D.T. Dimitrov et al[11]; G. Gabriellini[15]; S.M. Garba
et al[16]; and M.E. Songolo[17]; nonstandard finite difference (NSFD) schemes have also a potential to
preserve qualitative properties of the original system and to avoid ghost solutions [17, 18-22, 29].
The following are the organization of the rest of the paper: Section 2 introduce our recent model
constructed in [10]. In Section 3, we present the NSFD methodology. We construct a NSFD scheme for
the model and present a complete stability analysis of non-tumor states considering both immunotherapy
and chemotherapy. In section 4, the numerical simulations of the model is done for both immunotherapy
and chemotherapy drug and under different treatment strategies[30]. Section 5, presents the conclusion
of the study.
2 Model of multi-mutation and drug resistance with
immune-suppression caused by drug resistance tumor cells
Drug-induced resistance is a signifcant challenge faced by scientists nowadays and is one of the major
factors that lead to failure of therapeutic treatment of cancer. During the division of tumor cells there
is usually a change in genetics of the cells whereby some cells exhibit inherent resistance to a certain
chemotherapy drug. Additionally, some other cells will posses a gene that can transform them into drug-
induced resistant cells when the drug is administered[31]. These multi-mutation and drug resistance was
modeled by Feizabadi in [2]. In the previous study[10], we extended the model constructed in [2] to
include the effects of a basic immune system and of immunity-suppression caused by drug resistant
tumor cells. we first added the notion of immune system interaction as stated by Kirschner & Panetta
in [4] and of the immune-suppression established by Feizabadi & Witten in [1] to the core model of
Feizabadi in [2]. Then, we assumed that the immune system can not distinguish between the responsive
and the resistance tumor cells, so it acts on all the tumor cells. But those cells that are resistant are not
affected by the action of the effector cells. That is the effector cells affect only the drug-sensitive and the
mutated tumor cells, but not the resistant tumor cells. Thus the immune-suppression factors was assumed
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to be the resistant tumor cells. These resistant tumor cells attack the activated effector cells and lead to a
reduction in population of these effector cells which in turn result to a weakening of the immune system.
Therefore, the treatment strategy will be that of boosting the immunity (immunotherapy)[32]. It should
be noted that elimination of tumor population by chemotherapy drugs is dependent on the drug dosage[7,
8]. Also these drugs are cytotoxic to the drug-sensitive tumor cells, effector cells and the normal (body)
cells[1]. So, in the presence of both immunotherapy and chemotherapy drug, whereby the number of
effector and drug-sensitive tumor cells is significantly reduced due to chemotherapy, the dynamics of the
tumor, normal and effector cells can be described as follows:

dT (t)
dt
= rTT
(
1− T + TR + TM
KT
)
− (τ1 + τ2)T −
a1ET
g2 + T
− aT (1− e−MC)T ;
dTR(t)
dt
= rRTR
(
1− T + TR + TM
KR
)
+ τ1T + τM→R(1− e−MC)TM ;
dTM (t)
dt
= rMTM
(
1− T + TR + TM
KM
)
+ τ2T −
a2ETM
g4 + TM
− aTM (1− e
−MC
)TM − τM→R(1− e−MC)TM ;
dN(t)
dt
= rNN
(
1− N
KN
)
+ k(T + TR + TM )
(
1− T + TR + TM
T∗
)
− aN (1− e−MC)N ;
dE(t)
dt
= c(T + TR + TM )− µ2E +
p1EI
g1 + I
− αETR − aE(1− e−MC)E + aEE(1− e−Mi)E;
dI(t)
dt
=
p2E(T + TR + TM )
g3 + (T + TR + TM )
− µ3I;
T (0) = T0, TR(0) = TR0 , TM (0) = TM0 , N(0) = N0, E(0) = E0, I(0) = I0.
(1)
Where T (t), TR(t), TM (t), N(t), E(t) and I(t) are the total number respectively at a time t; of wild
tumor cells, drug-resistant tumor cells, mutated tumor cells, normal cells, effector cells with the unit of
cells and the concentration of IL-2[31, 33]. We assume that all of these tumor cells are growing under the
logistic law. Also, KN ,KT ,KM and KR are the carrying capacity of normal cells and the three types of
tumor cells with the unit of cells. The per capita growth rate for the drug-responsive tumor cells, mutated
tumor cells, drug-resistant tumor cells, and normal cells are expressed by rT , rM , rR, rN with the unit of
(time−1)[1]. The T ∗ is the critical size of the collection of tumor cells with the unit of cells. The second
term in the fourth equation represents the interaction between tumor and normal cells. This interaction is
chosen as a logistic growth function[1, 3]. In this term k with the units of (time−1) represent the tumor-
normal cell interaction rate. The term τ1T in first two equations expresses the transition of wild tumor
cells (responsive tumor cells) to intrinsically resistant tumor cells with a mutation rate of τ1(time−1).
The term τ2T in the first and the third equations represents the transition of wild tumor cells to mutated
tumor cells with a mutation rate of τ2(time−1).The effector cells are stimulated to grow based on two
terms: One is a recruitment term c(T + TR + TM ) due to the direct presence of the tumor, where the
parameter c models the antigenicity of the tumor. Antigenicity can be thought of as a measure of how
different the tumor is from ’self’[31, 33, 34]. The second is due to the presence of IL-2 hormones and is
given by the term p1EIg1+I [4]. This is of Michaelis-Menten form to indicate the saturated effects of immune
reponse[34]. p1 is the proliferation rate of immune cells and g1 is the half-saturation for the proliferation
term. To express the natural death of effector cells, the term −µ2E is added. In this term µ2 is the death
rate of the immune cells. The change in concentration of IL-2 is expressed as: p2E(T+TR+TM )g3+(T+TR+TM ) , which
is the activation due to the presence of the tumor. In this term, p2 is the production rate of the effector
molecules and g3 is the half-saturation of production. −µ3I , is the natural loss of IL-2 by the rate of µ3.
The infection of the effector cells by the resistant tumor cells reduce the size of the populations of the
effector cells. This is expressed as: −αETR with α the infection rate. The loss of tumor cells, due to the
immune-effector cells can be characterized with the Michaelis-Menten interaction terms: a1ETg2+T on wild
tumor cells[1] and a2ETMg4+TM on mutated tumor cells . Here, a1 is the rate of clearance of wild tumor cells as
a result of these two populations and g2 is the half-saturation for wild tumor cells clearance. a2 is the rate
of clearance of mutated tumor cells as a result of these two populations and g4 is the half-saturation for
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mutated tumor cells clearance[32, 35]. As suggested by Gardner in [9] the drug interaction may be struc-
tured as aφ(1− e−MC)φ. Here φ is the cell population number.36 The parameter C is the concentration
or amount of the drug at the tumor site at a specific time with the unit (mg.m−2)[37]. M is associated
to the drug pharmacokinetics and known as the drug efficiency coefficient with the unit of (m2.mg−1).
The coefficient aφ when φ = N,T, TM and E with the unit of (time−1) expresses the death rate induced
by the administered chemotherapeutic drug[31]. The function F (C) = aφ(1 − e−MC) is the fraction
cell kill for a given amount (concentration) of drug ”C”[36]. Thus the toxic effect of the administered
drug, which leads to the reduction in populations of cells, has been expressed by aT (1 − e−MC)T on
wild tumor cells, by aN (1 − e−MC)N on normal cells and by aE(1 − e−MC)E on effector cells. The
interaction of the drug with the mutated tumor cells partially kills them and partially turns them into
drug-resistant tumor cells. The toxic effect of the drug on the mutated tumor cells has been expressed
as aTM (1 − e−MC)TM . The term that expresses the conversion of mutated tumor cells to drug-resistant
tumor cells has been expressed by τM→R(1− e−MC)TM . In this term τM→R with the unit of (time−1)
expresses the conversion rate from mutated tumor cells to resistant tumor cells due to interaction with the
drug[31]. Additionally, the immunotherapeutic agent is described by the term aEE(1 − e−Mi)E and it
acts as an immune-boosting agent[32].
A solution of (1) is a function X : t ∈ J ⊂ R 7−→ X(t) =

T (t)
TR(t)
TM (t)
N(t)
E(t)
I(t)
 ∈ R
6
Let F : X ∈ R6 7−→ F (X) ∈ R6 with
F (X) =

rTT
(
1− T + TR + TM
KT
)
− (τ1 + τ2)T −
a1ET
g2 + T
− aT (1− e−MC)T ;
rRTR
(
1− T + TR + TM
KR
)
+ τ1T + τM→R(1− e−MC)TM ;
rMTM
(
1− T + TR + TM
KM
)
+ τ2T −
a2ETM
g4 + TM
− aTM (1− e
−MC
)TM − τM→R(1− e−MC)TM ;
rNN
(
1− N
KN
)
+ k(T + TR + TM )
(
1− T + TR + TM
T∗
)
− aN (1− e−MC)N ;
c(T + TR + TM )− µ2E+
p1EI
g1 + I
− αETR − aE(1− e−MC)E + aEE(1− e−Mi)E;
p2E(T + TR + TM )
g3 + (T + TR + TM )
− µ3I;
(2)
The system (1) becomes:
dX
dt
= F (X); X(0) = X0 =
(
T0;TR0 ;TM0 ;N0;E0; I0
)T
. (3)
From the existence and uniqueness theorem, F is C1 and then, first of all, there exists a solution of the
initial value problem (3) and, secondly, this is the only such solution. More precisely, there exists an
unique global solution which is non negative whenever the initial conditions are non negative.
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3 Stability Analysis of Non-tumor states Using Nonstandard Finite
difference Schemes
In this section, assuming that the immunotherapy drug is constant, we set aEE(1 − e−Mi)E = β with
β a parameter. The non-tumor state is the state defined by S∗ = (T ∗0 ;T
∗
R0
;T ∗M0 ;N
∗
0 ;E
∗
0 ; I
∗
0 ) where
all the tumor cells are zero. ie S∗ = (0; 0; 0;N∗0 ;E
∗
0 ; 0) with N
∗
0 = KN −
aNKN (1− e−MC)
rN
and
E∗0 =
β
µ2 + aE(1− e−MC) . This implies that all the tumor cells can be eliminated by the combination
of chemotherapy and immunotherapy drug if S∗ is stable. The stability analysis of this state is done in
the absence and in the presence of a second specific chemotherapy drug only toxic to TR. Note that this
second chemotherapy drug has been suggested by Feizabadi in [2] and expressed by aTR(1− e−MC2)TR
on resistant tumor cells.
Combining these informattions, the system (1) becomes:

dT (t)
dt
= rTT
(
1− T + TR + TM
KT
)
− (τ1 + τ2)T −
a1ET
g2 + T
− aT (1− e−MC)T ;
dTR(t)
dt
= rRTR
(
1− T + TR + TM
KR
)
+ τ1T + τM→R(1− e−MC)TM − aTR (1− e
−MC2 )TR
dTM (t)
dt
= rMTM
(
1− T + TR + TM
KM
)
+ τ2T −
a2ETM
g4 + TM
− aTM (1− e
−MC
)TM − τM→R(1− e−MC)TM ;
dN(t)
dt
= rNN
(
1− N
KN
)
+ k(T + TR + TM )
(
1− T + TR + TM
T∗
)
− aN (1− e−MC)N ;
dE(t)
dt
= c(T + TR + TM )− µ2E +
p1EI
g1 + I
− αETR − aE(1− e−MC)E + β;
dI(t)
dt
=
p2E(T + TR + TM )
g3 + (T + TR + TM )
− µ3I;
T (0) = T0, TR(0) = TR0 , TM (0) = TM0 , N(0) = N0, E(0) = E0, I(0) = I0.
(4)
To procced, We First define the nonstandard finite difference scheme and present the rules of its
construction as proposed by Mickens in [13].
3.1 Nonstandard Finite difference Schemes
A numerical scheme with a step size ∆t, that approximates the solution X(tk) of an autonomous system
dX
dt
= F (X);X(t0) = X0 where F is C1 can be written in the form:
D∆t(Xk) = F∆t(Xk) (5)
where D∆t(Xk) ' dX(tk)
dt
;Xk ' X(tk);F∆t(Xk) ' F (Xk) and tk ' t0 + k∆t (see, [11, 38, 39]).
Definition. 3.1[11, 28, 39, 40]: The scheme (5) is called a nonstandard finite difference scheme if at least
one of the following conditions is satisfied:
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1-D∆t(Xk) =
Xk+1 − ψXk
ϕ(∆t)
where ψ and ϕ are non negative functions depending on the
step-size ∆t and other parameters occurring in the differential equation, and, in addition,
satisfies the conditions: ψ(∆t) = 1 +O(∆t) and ϕ(∆t) = ∆t+O(∆t2).
2-F∆t(Xk) = g(Xk, Xk+1,∆t) where g is a nonlocal approximation of the right-hand side
of the system of the differential equation.
Definition. 3.2[11, 38, 39]: The nonstandard finite difference scheme is called elementary stable, if, for
any value of the step size, its only fixed points are those of the original differential system, the linear
stability properties of each fixed points being the same for both the differential system and the discrete
scheme.
Note 3.1 ([13, 41, 42]): The functions ψ and ϕ vary from one equation to another and no clear a
priori set of guidelines exist for determining them. However, In most applications, ψ is usually selected
to be 1; and ϕ (called the denominator function) is determined as follows: ϕ(∆t) =
1− e−R∗∆t
R∗
where
R∗ = max{|Ri|i=1;2....} with Ri = ∂f
∂xi
∣∣∣∣
X=0
and 0 < ϕ(∆t) <
1
R∗
Note also that nonstandard finite difference (NSFD) scheme are topologically equivalent to their original
system they approximate (for more details; see [14]).
Now, let present the rules for the construction of NSFD schemes as proposed by Mickens in [13] and
taken into account by [44, 45].
Rule 1: The order of the discrete derivatives must be equal to the order of the corresponding
derivatives of the differential equations.
Rule 2: Denominator functions for the discrete derivatives must, in general, be expressed in
terms of more complicated functions of the step-sizes than those conventionally used.
Rule 3: Nonlinear terms should, in general, be modeled nonlocally. However, sometimes
more general forms may be required, such as u2 = 2u2 − u2 −→ 2(uk)2 − uk+1uk.
Rule 4: Special conditions that hold for the solutions of the differential equations should
also hold for the solutions of the finite difference scheme.
Rule 5: The finite difference equations should not have solutions that dont correspond ex-
actly to solutions of the differential equations.
Definition. 3.3[13]: A nonstandard finite difference scheme is any discrete representation of a system of
differential equations that is constructed according to the above rules.
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3.2 Stability Analysis of the Non-tumor state S∗ in the absence of a second specific
chemotherapy drug only toxic to TR
Based on the above definitions and rules, the NSFD scheme of (4) in the absence of the second specific
chemotherapy drug only toxic to TR is given by:

Tn+1 − Tn
ϕ1(∆t)
= rTT
n+1
(
1− T
n + TnR + T
n
M
KT
)
− (τ1 + τ2)Tn+1 −
a1E
nTn+1
g2 + Tn
− aT (1− e−MC)Tn+1;
Tn+1R − TnR
ϕ2(∆t)
= rRT
n+1
R
(
1− T
n + TnR + T
n
M
KR
)
+ τ1T
n+1
+ τM→R(1− e−MC)TnM ;
Tn+1M − TnM
ϕ3(∆t)
= rMT
n+1
M
(
1− T
n + TnR + T
n
M
KM
)
+ τ2T
n+1 − a2E
nTn+1M
g4 + TnM
− aTM (1− e
−MC
)T
n+1
M − τM→R(1− e−MC)Tn+1M ;
Nn+1 −Nn
ϕ4(∆t)
= rNN
n+1
(
1− N
n
KN
)
+ k(T
n
+ T
n
R + T
n
M )
(
1− T
n + TnR + T
n
M
T∗
)
− aN (1− e−MC)Nn+1;
En+1 − En
ϕ5(∆t)
= c(T
n
+ T
n
R + T
n
M )− µ2En+1 +
p1E
nIn
g1 + In
− αEn+1TnR − aE(1− e−MC)En+1 + β;
In+1 − In
ϕ6(∆t)
=
p2E
n(Tn + TnR + T
n
M )
g3 + (Tn + TnR + T
n
M )
− µ3In+1;
(6)
Where: ϕ1(∆t) =
1− e−
(
rT−τ1−τ2−aT (1−e−MC)
)
∆t(
rT − τ1 − τ2 − aT (1− e−MC)
) ; ϕ2(∆t) = 1− e−rR∆t
rR
;
ϕ3(∆t) =
1− e−
(
rM−aTM (1−e−MC)−τM→R(1−e−MC)
)
∆t(
rM − aTM (1− e−MC)− τM→R(1− e−MC)
) ;
ϕ4(∆t) =
1− e−
(
rN−aN (1−e−MC)
)
∆t(
rN − aN (1− e−MC)
) ; ϕ5(∆t) = 1− e−(µ2+aE(1−e−MC))∆t
µ2 + aE(1− e−MC) ;
ϕ6(∆t) =
1− e−µ3∆t
µ3
In explicit form, we have:

T
n+1
=
Tn
1 + (τ1 + τ2 − rT )ϕ1(∆t) + aT (1− e−MC)ϕ1(∆t) + rT
(
Tn + TnR + T
n
M
KT
)
ϕ1(∆t) +
a1E
nϕ1(∆t)
g2 + Tn
;
T
n+1
R =
TnR + τ1T
n+1ϕ2(∆t) + τM→R(1− e−MC)TnMϕ2(∆t)
1− rRϕ2(∆t) + rR
(
Tn + TnR + T
n
M
KR
)
ϕ2(∆t)
;
T
n+1
M =
TnM + τ2T
n+1ϕ3(∆t)
1 + rM
(
Tn + TnR + T
n
M
KM
)
ϕ3(∆t) +
a2E
nϕ3(∆t)
g4 + Tn
− rMϕ3(∆t) + aTM (1− e−MC)ϕ3(∆t) + τM→R(1− e−MC)ϕ3(∆t)
;
N
n+1
=
Nn + k(Tn + TnR + T
n
M )
(
1− T
n+TnR+T
n
M
T∗
)
1 + rN
(
Nn
KN
)
ϕ4(∆t)− rNϕ4(∆t) + aN (1− e−MC)ϕ4(∆t)
;
E
n+1
=
c(Tn + TnR + T
n
M )ϕ5(∆t) +
p1E
nInϕ5(∆t)
g1 + In
+ βϕ5(∆t) + E
n
1 + µ2ϕ5(∆t) + aE(1− e−MC)ϕ5(∆t) + αTnR
;
I
n+1
=
p2E
n(Tn+TnR+T
n
M )
g3+(T
n+Tn
R
+Tn
M
)
ϕ6(∆t) + I
n
1 + µ3ϕ6(∆t)
;
(7)
With given initial condictions T (0) = T0, TR(0) = TR0 , TM (0) = TM0 , N(0) = N0, E(0) =
E0, I(0) = I0.
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It is clear that the non-tumor state of (4) is exactly the non-tumor state of (7).
Theorem. 3.1 The non-tumor state S∗ is unstable for every value of ∆t in the absence of the second
specific chemotherapy drug.
Proof. Linearizing the system (7) about the state S∗, the eigenvalues of the corresponding Jacobian ma-
trix is given by:
λ =
1
1 +
[
τ1 + τ2 − rT + aT (1− e−MC) + a1E
∗
0
g2
]
ϕ1(∆t)
, λ =
1
1− rRϕ2(∆t) ,
λ =
1
1 +
[
− rM + aTM (1− e−MC) + τM→R(1− e−MC) +
a2E
∗
0
g4
]
ϕ3(∆t)
,
λ =
1 +
[
− rN + aN (1− e−MC)
]
ϕ4(∆t)[
1 +
(
− rN + aN (1− e−MC) + rNN
∗
0
KN
)
ϕ4(∆t)
]2 = e−(rN−aN (1−e−MC))∆t,
λ =
1
1 +
[
µ2 + aE(1− e−MC)
]
ϕ5(∆t)
, λ =
1
1 + µ3ϕ6(∆t)
,
Since 0 < ϕ2(∆t) <
1
rR
, then
∣∣∣∣ 11− rRϕ2(∆t)
∣∣∣∣ > 1. Thus, the non-tumor state S∗ is unstable for
every value of ∆t in the absence of the second specific chemotherapy drug.
3.3 Stability Analysis of the Non-tumor state S∗ in the presence of a second spe-
cific chemotherapy drug only toxic to TR
The explicit form of the NSFD scheme of (4) is given by:

T
n+1
=
Tn
1 + (τ1 + τ2 − rT )ϕ1(∆t) + aT (1− e−MC)ϕ1(∆t) + rT
(
Tn + TnR + T
n
M
KT
)
ϕ1(∆t) +
a1E
nϕ1(∆t)
g2 + Tn
;
T
n+1
R =
TnR + τ1T
n+1ϕ2(∆t) + τM→R(1− e−MC)TnMϕ2(∆t)
1− rRϕ2(∆t) + aTR (1− e−MC2 )ϕ2(∆t) + rR
(
Tn + TnR + T
n
M
KR
)
ϕ2(∆t)
;
T
n+1
M =
TnM + τ2T
n+1ϕ3(∆t)
1 + rM
(
Tn + TnR + T
n
M
KM
)
ϕ3(∆t) +
a2E
nϕ3(∆t)
g4 + Tn
− rMϕ3(∆t) + aTM (1− e−MC)ϕ3(∆t) + τM→R(1− e−MC)ϕ3(∆t)
;
N
n+1
=
Nn + k(Tn + TnR + T
n
M )
(
1− T
n+TnR+T
n
M
T∗
)
1 + rN
(
Nn
KN
)
ϕ4(∆t)− rNϕ4(∆t) + aN (1− e−MC)ϕ4(∆t)
;
E
n+1
=
c(Tn + TnR + T
n
M )ϕ5(∆t) +
p1E
nInϕ5(∆t)
g1 + In
+ βϕ5(∆t) + E
n
1 + µ2ϕ5(∆t) + aE(1− e−MC)ϕ5(∆t) + αTnR
;
I
n+1
=
p2E
n(Tn+TnR+T
n
M )
g3+(T
n+Tn
R
+Tn
M
)
ϕ6(∆t) + I
n
1 + µ3ϕ6(∆t)
;
(8)
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Where ϕ2(∆t) =
1− e−
∣∣rR−aTR (1−e−MC2 )∣∣∆t∣∣rR − aTR(1− e−MC2)∣∣ With given initial condictions T (0) = T0, TR(0) =
TR0 , TM (0) = TM0 , N(0) = N0, E(0) = E0, I(0) = I0.
Theorem. 3.2 The non-tumor state S∗ is locally asymptotically stable for every value of ∆t in the pres-
ence of the second specific chemotherapy drug if the following condictions hold:
i) E∗0 >
g2
a1
[
rT − τ1 − τ2 − aT (1− e−MC)
]
ii) aTR(1− e−MC2) > rR
iii) E∗0 >
g4
a2
[
rM − aTM (1− e−MC)− τM→R(1− e−MC)
]
Remark 3.1: If one of conditions i), ii) and iii) fails, then S∗ is unstable.
Proof. Linearizing the system (8) about the state S∗, the eigenvalues of the corresponding Jacobian ma-
trix is given by:
λ =
1
1 +
[
τ1 + τ2 − rT + aT (1− e−MC) + a1E
∗
0
g2
]
ϕ1(∆t)
,
λ =
1
1 +
[− rR + aTR(1− e−MC2])ϕ2(∆t) ,
λ =
1
1 +
[
− rM + aTM (1− e−MC) + τM→R(1− e−MC) +
a2E
∗
0
g4
]
ϕ3(∆t)
,
λ =
1 +
[
− rN + aN (1− e−MC)
]
ϕ4(∆t)[
1 +
(
− rN + aN (1− e−MC) + rNN
∗
0
KN
)
ϕ4(∆t)
]2 = e−(rN−aN (1−e−MC))∆t,
λ =
1
1 +
[
µ2 + aE(1− e−MC)
]
ϕ5(∆t)
, λ =
1
1 + µ3ϕ6(∆t)
,
It follows that the non-tumor state S∗ is locally asymptotically stable for every value of ∆t in the presence
of the second specific chemotherapy drug if the conditions i), ii) and iii) hold.
Theorem. 3.3 The non-tumor state S∗ is globally asymptotically stable for every value of ∆t in the
presence of the second specific chemotherapy drug if the conditions i), ii) and iii) hold.
Proof. We must show that the sequence (Tn, TnR, T
n
M , N
n, En, In)n converge to S∗ = (0, 0, 0, N∗0 , E
∗
0 , 0)
for any positive initial conditions when the conditions i), ii) and iii) hold for every value of ∆t.
The state S∗ = (0, 0, 0, N∗0 , E
∗
0 , 0) is locally asymptotically stable for every value of ∆t when the con-
ditions i), ii) and iii) hold . Now suppose that for a certain k > 0, (T k, T kR, T
k
M , N
k, Ek, Ik) converge to
S∗ = (0, 0, 0, N∗0 , E
∗
0 , 0) and show that
(T k+1, T k+1R , T
k+1
M , N
k+1, Ek+1, Ik+1) converge also to S∗ = (0, 0, 0, N∗0 , E
∗
0 , 0).
(i) For T k+1,
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Tk+1 =
Tk
1 + (τ1 + τ2 − rT )ϕ1(∆t) + aT (1− e−MC)ϕ1(∆t) + rT
(
Tk + TkR + T
k
M
KT
)
ϕ1(∆t) +
a1E
kϕ1(∆t)
g2 + Tk
Then T k+1 −→ 0 when k −→∞.
(ii) For T k+1R ,
T k+1R =
T kR + τ1T
k+1ϕ2(∆t) + τM→R(1− e−MC)T kMϕ2(∆t)
1− rRϕ2(∆t) + aTR(1− e−MC2)ϕ2(∆t) + rR
(
T k + T kR + T
k
M
KR
)
ϕ2(∆t)
Then T k+1R −→ 0 when k −→∞.
(iii) For T k+1M ,
Tk+1M =
TkM + τ2T
k+1ϕ3(∆t)
1 + rM
(
Tk + TkR + T
k
M
KM
)
ϕ3(∆t) +
a2Ekϕ3(∆t)
g4 + Tk
− rMϕ3(∆t) + aTM (1 − e−MC)ϕ3(∆t) + τM→R(1 − e−MC)ϕ3(∆t)
Then T k+1M −→ 0 when k −→∞.
(iv) For Nk+1,
Nk+1 −N∗0 =
Nk + k(Tk + TkR + T
k
M )
(
1− T
k+TkR+T
k
M
T∗
)
−N∗0
(
1 +
rNN
k
KN
ϕ4(∆t)− rNϕ4(∆t) + aN (1− e−MC)ϕ4(∆t)
)
1 +
rNN
k
KN
ϕ4(∆t)− rNϕ4(∆t) + aN (1− e−MC)ϕ4(∆t)
Then Nk+1 −N∗0 −→ 0 when k −→∞. Thus, Nk+1 −→ N∗0 when k −→∞
(v) For Ek+1,
Ek+1 − E∗0 =
c(Tk + TkR + T
k
M )ϕ5(∆t) +
p1E
kIkϕ5(∆t)
g1 + Ik
+ βϕ5(∆t) + E
k − E∗0
(
1 + µ2ϕ5(∆t) + aE(1− e−MC)ϕ5(∆t) + αTkR
)
1 + µ2ϕ5(∆t) + aE(1− e−MC)ϕ5(∆t) + αTkR
Then Ek+1 − E∗0 −→ 0 when k −→∞. Thus, Ek+1 −→ E∗0 when k −→∞
(vi) For Ik+1,
Ik+1 =
p2E
k(Tk+TkR+T
k
M )
g3+(Tk+TkR+T
k
M )
ϕ6(∆t) + I
k
1 + µ3ϕ6(∆t)
Then Ik+1 −→ 0 when k −→∞.
Hence, the non tumor state S∗0 is globally asymptotically stable for every value of ∆t in the presence
of the second specific chemotherapy drug when the conditions i), ii) and iii) hold.
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4 Numerical simulations under different therapeutic approaches
The numerical simulations of the model (1) is done in MATLAB using ode45 function. The parameter
values used for these simulations are given in Table 1.
Table 1: Description of simulation parameters.
Parameters Units Description Estimated value Reference Source
rT Day
−1 Growth rate for wild tumor cells 0.15 [10]
rR Day
−1 Growth rate for resistant tumor cells 0.015 [10]
rM Day
−1 Growth rate for mutated tumor cells 0.1515 [10]
rN Day
−1 Growth rate for the normal cells 0.5 [2]
KT ;KR;KM ;KN Cells Carrying capacity of cells 106 [2]
τ1 Day
−1 Mutation rate 10−4 [2]
τ2 Day
−1 Mutation rate 10−5 [10]
a1 Day
−1 rate of clearance of wild tumor cells 1.5 [10]
g2 Cells Half-saturation for wild tumor cells clearance 105 [1]
τM→R Day−1 conversion rate 10−4 [2]
a2 Day
−1 rate of clearance of mutated tumor cells 1.5 [10]
g4 Cells Half-saturation for mutated tumor cells clearance 105 [10]
k Day−1 tumor-normal cell interation rate 0.028 [1]
T∗ Cells Critical size of tumor 3× 105 [2]
c Day−1 Antigenicity 0.5 [10]
µ2 Day
−1 Death rate of immune cells 0.003 [10]
µ3 Day
−1 Death rate of IL-2 10 [1]
p1 Day
−1 Proliferation rate of immune cells 0.1245 [1]
g1 Cells Half-saturation for the proliferation 2× 107 [1]
p2 Day
−1 Production rate of IL-2 5 [1]
g3 Cells Half-saturation of production 30 [1]
α Day−1 Effector-Resistant tumor cells interation rate 3× 10−4 [1]
aT Day
−1 death rate induced by the chemotherapeutic drug on T 0.15 [2]
aTM Day
−1 death rate induced by the chemotherapeutic drug on TM 0.10 Assumed
M m2.mg−1 Pharmacokinetics parameter 1 [2]
aN Day
−1 death rate induced by the chemotherapeutic drug on N 0.05 Assumed
aE Day
−1 death rate induced by the chemotherapeutic drug on E 0.05 Assumed
aEE Day
−1 Immune boosting rate induced by the immunotherapy drug 0.10 Assumed
i mg.m−2 Concentration of immunotherapy drug 0.2 Assumed
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4.1 Constant concentration of the chemotherapy drug (C = 0.2mg.m−2) and
drug-induced resistance
Assumptions
• The chemotherapy drug is administered at t = 600 days.
• The mutation from the group of wild tumor cells T to the group of mutated tumor cells TM starts at
t = 0 days.
•As the chemotherapy drug is introduced the conversion from the group of mutated tumor cells TM to the
group of resistant tumor cells TR starts immediately (ie at t = 600 days). Thus the immune-suppression
by the resistant tumor cells starts also immediately
Note that the interaction of the chemotherapy drug with the mutated tumor cells partially kills them and
partially turns them into drug-resistant tumor cells. Those that remain will grow and create new cells that
carry the mutated gene, which potentially can create drug-induced resistance.
Fig. 1: Simulation results under the therapeutic approach 4.1.
From t = 100 days to t = 500 days the tumor cells are controlled by the immune system. However
from t = 550 days these tumor cells started to grow (see Fig. 1a and 1c). After the introduction of the
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chemotherapy drug, the wild tumor cells T started to die out from the system. The mutated tumor cells
TM are still in the system by growing. They could be killed by the immune system, but due to the logistic
grow of resistant tumor cells which is suppressing the immune system from t = 600, they started to grow
(see fig. 1c and 1d). The evolution of normal cells can be seen through the figure 1a.
4.2 Constant concentration of the chemotherapy and immunotherapy drug (C =
0.2mg.m−2 and i = 0.2mg.m−2) and drug-induced resistance.
The assumptions made in the subsection 4.1 are also taken into account here. Moreover, the immunother-
apy drug is administered at t = 800 days.
Fig. 2: Simulation results under the therapeutic approach 4.2.
The effectiveness of the immunotherapy drug can be seen with Fig. 2a and 2b. Indeed, the mutated tumor
cells that were still growing in the presence of the chemotherapy drug began to die out from t = 850
days after the introduction of the immunotherapy drug at t = 800 days. Thus, this therapeutic approach
is effective on sensitive tumor cells.
4.3 Decreasing concentration of the chemotherapy drug (C(t) = 0.2×e−10−3tmg.m−2),
drug-induced resistance and constant concentration of the immunotherapy
drug (i = 0.2mg.m−2)
The assumptions made in the subsection 4.1 are also taken into account here. However, the concentration
of the chemotherapy drug decreases exponentially over time. The immunotherapy drug is administered
at t = 800 days.
89
Fig. 3: Simulation results under the therapeutic approach 4.3.
The results of the simulations 3a and 3b are almost similar to those obtained in the therapeutic approach
4.2. All the sensitive tumor cells disappear from the system at the end of the simulation time. However,
resistant tumor cells grow more slowly in Fig. 3b than in Fig. 2b. This is due to the decrease in the
concentration of the chemotherapeutic drug used.
4.4 Decreasing concentration of the chemotherapy drug (C(t) = 0.2×e−10−3tmg.m−2)
and both intrinsic and drug-induced resistance.
Assumptions
• The mutation from the group of wild tumor cells T to the group of resistant tumor cells TR starts at
t = 0 days.
• The mutation from the group of wild tumor cells T to the group of mutated tumor cells TM starts at
t = 0 days.
• The chemotherapy drug is administered at t = 650 days. So, the conversion from the group of mutated
tumor cells TM to the group of resistant tumor cells TR starts immediately (ie at t = 650 days).
As suggested in Ref. 2, We introduce in addition a second chemotherapy drug considered constant over
time with a higher dosage
(
aTR(1 − e−MC2)TR with aTR = 0.15 and C2 = 0.6mg.m−2
)
that is
specifically toxic to drug resistant tumor cells (see Fig. 4c and 4d). This drug is introduced at t = 850
days.
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Fig. 4: Simulation results under the therapeutic approach 4.4.
Since the resistant tumor cells started to grow, the immune-suppression also started at the begining of
the simulation time. However, the immune system was able to fight the mutated tumor cells. But the
wild tumor cells is growing as well and become detectable around t = 550 days to the point where the
chemotherapy drug administreted at t = 650 days was not able to fight the wild tumor cells (see Fig. 4a
and 4b).
Through Fig. 4c and 4d, the second chemotherapy drug administreted at t = 850 days kill the resistant
tumor cells and from that moment the immune system was able to fight the wild tumor cells. It can be
concluded that the combination of these two chemotherapy drug is more successful therapeutic approach
to control all types of tumor cells.
4.5 Increasing concentration of the chemotherapy drug (C(t) = 1−e−10−3tmg.m−2)
and both intrinsic and drug-induced resistance.
The assumptions made in the subsection 4.4 are also taken into account here. However, the concentration
of the chemotherapy drug increases from 0 to 1 over time.
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Also, We introduce in addition a second chemotherapy drug considered constant over time with a higher
dosage
(
aTR(1 − e−MC2)TR with aTR = 0.15 and C2 = 0.6mg.m−2
)
that is only toxic to drug
resistant tumor cells specifically (see Fig. 5c and 5d). This drug is introduced at t = 850 days.
Fig. 5: Simulation results under the therapeutic approach 4.5.
Contrary to the simulation results in Fig. 4a and 4b, here the wild tumor cells disappear from the system
at the end of the simulation time. This is due to the increase in the concentration of the chemotherapy
drug administreted from t = 650 days (see Fig. 5a and 5b). Fig. 5c and 5d show that the second
chemotherapy drug administreted at t = 850 days kill the resistant tumor cells. It can be also concluded
that the combination of these two chemotherapy drug is more successful therapeutic approach to control
all types of tumor cells.
5 Conclusion
In this study, a nonstandard finite difference scheme for our previous multi-mutation and drug resistance
model was constructed to analyze the stability of non-tumor state in the presence of both immunother-
apy and chemotherapy. Conditions under which tumor can be eliminated was identified. Numerical
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simulations of the model in the presence of both immunotherapy and chemotherapy and under different
treatment strategies was performed with the aid of MATLAB sofware usingode45 function. Two differ-
ents treatment strategies was proposed when the dynamical system expresses intrinsic and drug induced
resistance with immune suppression.
The non-tumor state is stable (ie tumor can be eliminated) under conditions in the presence of both
immunotherapy and chemotherapy when a second specific chemotherapy drug only toxic to resistant
tumor cells (TR) is introduced. It can be seen through numerical simulations that the treatment strategies
in section 4.4 and 4.5 could be the more successful therapeutic approach to control both the progression of
cancer as well as the existing resistance. Some open concerns include whether mutations, the conversion
and the infection occur at a constant rate or whether the rates may be affected by the immunotherapy drug
and the chemotherapy drug.
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